Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies.
Deng Z, Jin M, Ou C, Jiang W, Zhao J, Liu X, Sun S, Tang H, He B, Cai S, Chen P, Wu P, Liu Y, Kang J, Zhang Y, Huang M, Xu J, Huang K, Li Q, Zhang X, Fu X, Wang C, Shen H, Zhu L, Shi G, Qiu Z, Wen Z, Wei X, Gu W, Wei C, Wang G, Chen P, Xie L, Lin J, Tang Y, Han Z, Chung KF, Zhang Q, Zhong N; C-BIOPRED Consortium.
Deng Z, et al. Among authors: wu p.
Chin Med J (Engl). 2023 Jan 20;136(2):230-232. doi: 10.1097/CM9.0000000000002556.
Chin Med J (Engl). 2023.
PMID: 36752798
Free PMC article.
No abstract available.